Yesterday, Cellular Dynamics International (CDI) released a press release announcing that they have reached an agreement with AstraZeneca. One of the goals of their agreement, is to collaborate for the development of new stem cell treatments based on induced pluripotent stem cells. About 15 days ago, CDI had also announced a partership with GE HealthCare Life Sciences
According to the agreement, AstraZeneca is licensed to commercially use CDI's "Icell" and "MyCell" products. Some of the purchased Icell products are:
- iCell Cardiomyocytes
- iCell Neurons
- iCell Endothelial Cells
- iCell Hepatocytes
AstraZenega wishes to use the products of the Icell and Mycell line to genetically engineer and manufacture cells from specific patient groups, for use as in vitro disease models.
Video about Cellular Dynamics
As part of their agreement, the two companies will also work together for the development of new types induced pluripotent stem cells.
The financials terms of the agreement were not disclosed.
Promotional video of AstraZeneca
Read the official press release here